Figure 2.
Differences in UBA7 expression according to clinicopathological characteristics. Significant differences were observed according to (A) molecular subtype of breast cancer, and (B) PR, (C) ER and (D) HER2 expression. However, no significant differences were observed according to (E) radiation therapy, (F) neoadjuvant treatment and (G) targeted molecular therapy. UBA7, ubiquitin-like modifier-activating enzyme 7; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.